Last updated: 2026-10-16 22:24:00. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.
Oculis Holding AG (OCS) operates in the -- sector and is listed on NASDAQ. The stock is currently priced at $7.27, with a market capitalization of $441.59M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $7.11 to $34.48. This page covers its latest market performance, valuation, price trends and company information.
$441.59M | |
$7.33 | |
$34.48 | |
$6.26 | |
$7.40 | |
230.01K | |
264.14K | |
-- | |
$34.48 | |
$7.11 | |
-- | |
-- |
Oculis Holding AG (OCS) is trading at $7.27 in after-hours trading as of 2026-10-16 22:19:00, down 1.76% ($0.13) from the regular-session close of $7.40.
After-hours trading shows how investors are pricing OCS after the regular session closes. The current after-hours price is below the regular-session close, indicating cautious after-hours sentiment.
Over the past seven days, Oculis Holding AG (OCS) moved from $8.50 to $7.27, representing a decline of 14.45% ($1.23).
The stock traded between $7.11 and $8.83 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 352.70 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 0.6%
OCS is currently trading at $7.27, placing it 0.6% of the way from its 52-week low of $7.11 to its 52-week high of $34.48. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Oculis Holding AG is a biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The Company has locations in five countries: Switzerland, Iceland, France, U.S. and Hong Kong.
| Employees | 67 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Oculis Holding AG (OCS) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.